Difference between revisions of "Ripretinib (Qinlock)"
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/kit-pdgfr-inhibitor-dcc-2618 NCI Drug Dictionary]: An orally...") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the package insert. |
| − | ==Diseases for which it is | + | ==Diseases for which it is established ''(work in progress)''== |
*[[Gastrointestinal stromal tumor]] | *[[Gastrointestinal stromal tumor]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2020-05-15: Approved for adult patients with advanced [[Gastrointestinal stromal tumor|gastrointestinal stromal tumor (GIST)]] who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ''(Based on INVICTUS)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *2021-11-18: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' DCC-2618 | *'''Code name:''' DCC-2618 | ||
| Line 28: | Line 29: | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
| + | [[Category:EMA approved in 2021]] | ||
Latest revision as of 00:05, 6 July 2024
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, DCC-2618 targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the package insert.
Diseases for which it is established (work in progress)
History of changes in FDA indication
- 2020-05-15: Approved for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. (Based on INVICTUS)
History of changes in EMA indication
- 2021-11-18: Initial authorization
Also known as
- Code name: DCC-2618
- Brand name: Qinlock